Abstract
Pediatric Osteosarcoma (OS) is a highly aggressive type of cancer that represents 2.7% of all pediatric cancers...
Highlights
Pediatric Osteosarcoma (OS) is a highly aggressive type of cancer that represents 2.7% of all pediatric cancers [1]
Chemotherapy lies at the centre of all strategies implemented in the medical management of Pediatric Osteosarcoma (OS)
Focus should be turned onto novel areas of research, as they will hold the key for any future advancements to come
Summary
Pediatric Osteosarcoma (OS) is a highly aggressive type of cancer that represents 2.7% of all pediatric cancers [1]. It usually manifests in the first two decades of life, and it poses a particular challenge to treat, due to its highly unstable genetic and epigenetic nature [2]. The management of this disease has evolved greatly, via an evolution that paralleled the changing landscape of science and technology during the late twentieth century. This has come through improvements in; (i) means of early diagnosis, (ii) medical and immunological treatments, (iii) surgical technologies and (iv) radiotherapeutic techniques. It is important to understand the current state of the art regarding the management of OS, acknowledge its limitations and appreciate all research attempts in the field that might yield a useful addition to the standard of care in the near future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
